Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
March 29 2019 - 4:15PM
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical
company dedicated to the discovery, development and
commercialization of novel therapies for the treatment of cancer
and related conditions, today announced the appointment of Jordan
S. Kanfer, Managing Director, Convertible and Equity Research at
Opti Capital Management, to its Board of Directors, effective April
1, 2019. Mr. Kanfer will replace SongYi Zhang, J.D., who is
stepping down.
“Jordan will be a tremendous asset to our Board. As an
experienced global fund manager and life sciences investor he has a
broad understanding of the investment community and global
healthcare market,” said Dr. Johnson Lau, Chairman and Chief
Executive Officer of Athenex. “Additionally, Jordan has
demonstrated exceptional leadership qualities in building teams and
overseeing operations as a consultant and at medical centers and
laboratories. We look forward to his contributions as we continue
progressing as a public company.”
Mr. Kanfer stated, “I am honored to join the Board of Directors
for Athenex, an innovative anti-cancer company pioneering the way
for oral chemotherapy. With the global market for cancer treatments
expected to reach $150 billion next year and the current treatment
methods unable to meet the demands of cancer and precancerous
patients seeking varied therapeutic options, I am eager to
collaborate with this dynamic team as it realizes its goal of
bringing its innovative therapies to market.”
Jordan Kanfer is a Managing Director, Convertible and Equity
Research at Opti Capital Management, where he is responsible for
all aspects of healthcare investing for both credit and equity
components. He is currently a member of the American College of
Healthcare Executives and serves on the Board of Advisors for dB
Diagnostics Systems. Mr. Kanfer’s investment management experience
includes working in various managerial and senior analyst roles,
most notably for Arrowgrass Capital Partners, TPG-Axon Capital,
JANA Partners and SAC Capital. Prior to working on the buy-side,
Mr. Kanfer was a Vice President at Goldman, Sachs & Co., and
previously worked in the healthcare industry in multiple consulting
and operations capacities. He received an M.P.H. from the
University of Massachusetts at Amherst and a B.A. in history from
Yeshiva University.
“We thank SongYi for his tremendous guidance, generosity and
commitment during his tenure as a board member. As an early
investor in Athenex, SongYi’s insights were invaluable, as we
transformed from a very early-stage company to one with late stage
clinical assets and multiple technology platforms in oncology,”
added Dr. Lau.
Mr. Zhang commented, “I have great respect for Athenex and the
management team, and have appreciated my term on the Board. Having
participated in early investments in Athenex and watched Athenex
mature from pre-IPO to a robust public company with a versatile
product pipeline, I firmly believe that the Company is well on its
way to realizing its vision of bringing more safe, effective, and
tolerable treatments to cancer patients. I wish Athenex continued
progress in developing its impressive clinical stage assets and
creating a path for commercialization.”
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; and multiple locations
in Chongqing, China. For more information, please
visit www.athenex.com.
CONTACTSInvestor Relations:Tim McCarthy
Managing Director, LifeSci Advisors, LLC Tel: +1
716-427-2952 Direct: +1 212-915-2564
Athenex, Inc.: Randoll Sze Chief Financial Officer
Email: randollsze@athenex.com Jacqueline Li Corporate
Development and Investor Relations
Email: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024